Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC

RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab

Trial Locations (1)

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors

lead

Guangdong Provincial People's Hospital

OTHER